CogState Stock

CogState Equity

The The Equity of CogState (CGS.AX) as of Jun 23, 2026 is 47.9 T USD.In the previous year, The Equity was 40.92 T USD — a change of 17.05% (higher).

Equity

47.9 TUSD

YoY

17.05%

Last updated:

In 2026, CogState's equity was 47.9 T USD, a 17.05% increase from the 40.92 T USD equity in the previous year.

Access this data via the Eulerpool API

CogState Stock analysis

What does CogState do? CogState Ltd is an Australian company specializing in the development of innovative cognitive tests. The company was founded in 1999 and is based in Melbourne, Australia. It conducts computer-based cognitive tests to gather information about the cognitive functioning of patients and athletes. The CogState tests are specifically designed to measure cognitive abilities in areas such as perception, reaction time, memory, and attention. The business model of CogState is based on the development, marketing, and sale of cognitive test products. The company generates a significant portion of its revenue through licensing its tests to pharmaceutical and biotech companies that want to test their medications or therapies more effectively. CogState also has a strong presence in the sports industry, offering its tests to sports teams and individual athletes. CogState was founded in 1999 by Paul Maruff, a neuropsychologist, who was searching for better and more effective ways to conduct cognitive tests. Initially, the tests developed by CogState were exclusively for medical research, but it was quickly discovered that they could be useful in other areas as well. In 2004, Richard Kimber joined the company as CEO and Chairman, bringing his experience from the biotechnology industry. CogState offers a variety of cognitive tests for various applications, including clinical trials, sports performance analysis, and brain injury treatment. The tests are licensed by different companies and organizations that use them to test the effects of medications and therapies on cognitive functions or to assess performance and injuries in sports. One example of a CogState product is the AX Continuous Tracker Test. This test was developed for clinical use and allows for continuous and accurate measurement of cognitive functions in patients with psychiatric and neurological disorders. Another application is the SPARQ test for athletes, which allows for the measurement and improvement of athletes' cognitive abilities. In summary, CogState Ltd is a leading company in the field of cognitive tests. The company specializes in developing innovative cognitive tests for the specific requirements of pharmaceutical and biotech companies, as well as sports organizations. The tests are used worldwide by various organizations and have a significant impact on the treatment of psychiatric and neurological disorders, as well as performance and injury analysis in sports. CogState is one of the most popular companies on Eulerpool.

Equity Details

Analyzing CogState's Equity

CogState's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding CogState's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating CogState's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

CogState's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in CogState’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about CogState stock

The Equity of CogState amounted to 40.92 T USD 47.9 T

Access this data via the Eulerpool API

Balance Sheet — CogState

All Key Metrics — CogState